Last reviewed · How we verify
Ifosfamid
At a glance
| Generic name | Ifosfamid |
|---|---|
| Also known as | Ifex |
| Sponsor | Polish Lymphoma Research Group |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Testicular Germ Cell Tumor
Common side effects
- Alopecia
- Nausea/Vomiting
- Hematuria (without mesna)
- Leukopenia <1 x 103/µL
- Anemia
- Hematuria (with mesna)
- Central nervous system toxicity
- Macrohematuria (without mesna)
- Infection
- Thrombocytopenia <50 x 103/µL
- Phlebitis
- Hepatotoxicity
Serious adverse events
- Cardiotoxicity
- Macrohematuria (with mesna)
- Thrombocytopenia with bleeding (fatal outcome reported)
- Encephalopathy with coma and death
- Hemorrhagic cystitis
- Renal dysfunction
- Renal structural damage
Key clinical trials
- Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (PHASE2)
- First Line TIP in Poor Prognosis TGCTs. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |